alitretinoin

Analysts believe the medication -- called alitretinoin -- may have the potential be a multimillion-dollar earner if it wins approval.

Eczema Drug May Find a Niche Cassandra Petrakis Zwahlen 2008

Goldman Sachs estimates alitretinoin could fetch $220 million in its best years.

Eczema Drug May Find a Niche Cassandra Petrakis Zwahlen 2008

Potentially, regulators in Europe and the U.S. could decide the benefits of the drug don't outweigh the risks, even though alitretinoin is "clearly efficacious," Ms. Jerman said.

Eczema Drug May Find a Niche Cassandra Petrakis Zwahlen 2008

Basilea said it sees significant commercial potential for alitretinoin.

Eczema Drug May Find a Niche Cassandra Petrakis Zwahlen 2008

The risks arise because alitretinoin is a retinoid.

Eczema Drug May Find a Niche Cassandra Petrakis Zwahlen 2008

Basilea and analysts expect European regulators to make a decision on alitretinoin before the end of the year.

Eczema Drug May Find a Niche Cassandra Petrakis Zwahlen 2008

A phase III clinical program on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S.

Reuters: Press Release 2011

Toctino® (alitretinoin) - the only therapy approved for adults with severe chronic hand eczema (CHE) unresponsive to topical Basilea currently markets Toctino® in Denmark, Finland, France, Germany, Norway, Switzerland and the United Kingdom.

Reuters: Press Release 2011

Regarding the Toctino® alitretinoin U.S. phase III HANDEL study, all patients completed their treatment cycle by the end of June and Basilea expects to report top line efficacy and safety data around year-end 2011.

Reuters: Press Release 2011

A phase III clinical program on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S.

Reuters: Press Release 2011